Clinical Trials Logo

Invasive Meningococcal Disease clinical trials

View clinical trials related to Invasive Meningococcal Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT04184336 Recruiting - Clinical trials for Invasive Meningococcal Disease

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Start date: January 2016
Phase:
Study type: Observational

Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.

NCT ID: NCT01732627 Completed - Meningitis Clinical Trials

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Start date: November 12, 2012
Phase: Phase 2
Study type: Interventional

Primary objectives: - To describe the antibody responses to meningococcal serogroups A, C, Y, and W 135, measured by serum bactericidal assay using human complement (hSBA) and baby rabbit complement (rSBA), induced by a single dose of Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein (MenACYW) Conjugate vaccine or Menomune® - A/C/Y/W 135. - To describe the safety profile of a single dose of MenACYW Conjugate vaccine or Menomune® - A/C/Y/W 135.

NCT ID: NCT01272180 Completed - Clinical trials for Invasive Meningococcal Disease

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines

NCT ID: NCT01129518 Completed - Clinical trials for Invasive Meningococcal Disease

Can we Reduce the Number of Vaccine Injections for Children?

MALTA
Start date: June 2010
Phase: Phase 4
Study type: Interventional

This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy. 498 infants will be enrolled in this multi-centre trial. Participants will receive either 0, 1, or 2 priming doses of a MenC-CRM197 conjugate vaccine or 1 priming dose of a MenC-TT conjugate vaccine in the first year of life, with all groups receiving a dose of a combination Hib-MenC-TT vaccine at 12 months, as well as all other concurrent routine vaccinations. All groups will also be further divided into 2 groups to receive their routine vaccines in either consistent or alternating limbs to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs. Immune responses will be assessed at 5, 12, 12months +6 days, 13 and 24 months of age.